The first CNS Brain Mets Symposium hosted by MEMORIAL SLOAN KETTING to be hosted 3 March
There is research or even KZA collaborations - whereby a brain penetrant PI3K inhibitor (eg Paxalisib)...may work in combination with all these mutations. Plus it was MSK itself (this header)- who delivered 100 % success in a Paxalisib / radiation study in CNS Brain Mets.
(e.g. Her2, EGFR, KRAS, CDK, BRAF, and ALK)
So obviously going to be off extreme interest here for Kaza. (CNS Brain defaults to PI3K Paxalisib, to some degree - my words)
(Just quickly - it seems the ATM will come to an end - and now investors can sit back and await a whole range of blockbuster news, without this news being heavily sold into by the ATM). Probably more dilution with Monday or Tuesdays news - but the thing is, the capitalization of the company, is so hopelessly low - that a once off batch of capital raise shares, pretty much does not matter).
18 times in 7 months, of ATM sold into every snippet of good news - destroyed sentiment, bu t now the ATM will come to an end.
1st Annual Symposium on Advanced Therapeutics for Brain Metastasis: Moving the Needle and Controversies at the Cutting Edge
Date & Location
Friday, March 3, 2023, 8:00 AM - 5:00 PM, Online, New York, NY
Specialties Specialties - Breast Medical Oncology, Genitourinary Oncology, Gynecologic Oncology, Medical Oncology, Neuro-Oncology, Neuroradiology, Neurosurgery, Oncology and Hematology, Radiation Oncology, Solid Tumor Oncology, Thoracic Medical Oncology
Overview
This complimentary virtual symposium will provide clinicians and translational scientists with updates on the latest developments in brain metastasis treatment and research, CNS-specific outcomes from molecular and traditional cancer histology viewpoints. Recent evidence for brain metastasis activity will be highlighted for key medical targets (e.g. Her2, EGFR, KRAS, CDK, BRAF, and ALK), and leading experts will review brain metastasis prognosis across the cancers commonly resulting in this (lung, breast, and melanoma).
Highlights of this didactic and case-based program include:
Sessions on the recent developments in local therapy, a review of the role of laser interstitial thermal therapy, brachytherapy, and external beam radiation techniques.
In recognition of the many complex treatment interactions imposed by multimodality treatment often necessary, a 'Key Controversies' session will speak to major areas of clinical difficulty; for example: how to distinguish the recurrent disease from radiation necrosis on imaging studies, when to change therapy with CNS-only progressive disease, which leptomeningeal metastasis interventions are currently worthwhile, and special considerations regarding steroid use and radiation therapy for patients requiring immunotherapy.
Key scientists will discuss promising translational and clinical trial approaches including targeting metastasis-initiating cells and window-of-opportunity studies.
Given the special challenge of early detection, a dedicated session will cover state-of-the-art molecular imaging techniques, the evidence for/against imaging surveillance in standard-risk cancers, and the current state of liquid biopsy.
A roundtable discussion with participants from several centers will share their experiences and best practices with multidisciplinary team care and discuss areas for improvement.
Finally, a multidisciplinary tumor board will review multifaceted cases, highlighting the interplay of various treatment options.
There will be ample opportunity for networking with speakers and other participants in this virtual meeting. Who Should Attend
This symposium is intended for neurosurgeons, radiation oncologists, neurologists and neuro-oncologists, physicians in training, and other allied health professionals who treat and manage patients with metastatic disease.
Objectives
Describe the current multimodal landscape of brain metastasis treatment
Identify key clinical controversies in brain metastasis management
Discuss barriers to improved treatments and potential research strategies (e.g. limited CNS activity of systemic anti-cancer treatments, side effects of local treatments, limited survival, and unclear endpoints)
Registration This symposium is complimentary. Please complete registration through the 'Register' tab above in order to attend (registration is required).
Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our Help
If you are registered for this symposium and unable to attend, please email [email protected] to cancel your registration. Live Virtual Format
This live virtual program will be delivered using Zoom. We encourage all attendees to download the Zoom app prior to the start of the course (zoom.us/download). CME credit will be offered for this live virtual program. Detailed access and credit instructions will be emailed to attendees prior to the start of the course.
Detailed access instructions will be emailed to registered attendees prior to the start of the program.
KZA Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
